Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group

Leukemia

Volumn 26, Issue 7, 2012, Pages 1730-1741

  Westers, T M ^a   Ireland, R ^b   Kern, W ^c   Alhan, C ^a   Balleisen, J S ^d   Bettelheim, P ^e   Burbury, K ^f   Cullen, M ^g   Cutler, J A ^h   Della Porta, M G ⁱ   Drager A M ^a   Feuillard, J ^j   Font, P ^k   Germing, U ^d   Haase, D ^l   Johansson, U ^m   Kordasti, S ^b   Loken, M R ^h   Malcovati, L ⁱ   Te Marvelde, J G ⁿ   Matarraz, S ^o   Milne, T ^b   Moshaver, B ^b   Mufti, G J ^b   Ogata, K ^q   Orfao, A ^o   Porwit, A ^r   Psarra, K ^s   Richards, S J ^g   Subira D ^t   Tindell, V ^b   Vallespi, T ^u   Valent, P ^v   Van Der Velden, V H J ⁿ   De Witte, T M ^p   Wells, D A ^h   Zettl, F ^l   Bene M C ^w   Van De Loosdrecht, A A ^a   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e ELISABETHINEN HOSPITAL   (Austria)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h HEMATOLOGICS INC   (United States)

ⁱ UNIVERSITY OF PAVIA   (Italy)

^j DUPUYTREN UNIVERSITY HOSPITAL   (France)

^k HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^l UNIVERSITY OF GÖTTINGEN   (Germany)

^m UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o Centro de Investigacion del Cancer   (Spain)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^q NIPPON MEDICAL SCHOOL   (Japan)

^r KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^s EVANGELISMOS HOSPITAL   (Greece)

^t HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^u HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^v MEDICAL UNIVERSITY OF VIENNA   (Austria)

^w UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

consensus; ELN; flow cytometry; myelodysplastic syndromes; standardization

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CLINICAL PRACTICE; DYSPLASIA; EUROPE; FLOW CYTOMETRY; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STANDARDIZATION; WORKSHOP;

BONE MARROW; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTERNATIONAL AGENCIES; MYELODYSPLASTIC SYNDROMES; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; REFERENCE STANDARDS; SOCIETIES, SCIENTIFIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84863785114     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.30     Document Type: Article

References (66)

1. Cazzola M, la Porta MG, Travaglino E, Malcovati L. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol 2011; 38: 627-634.
2. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31: 727-736.
3. Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 3887-3896.
4. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394-403.
5. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VHJ, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low-and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111: 1067-1077.
6. van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009; 94: 1124-1134.
7. Brunning R, Orazi A, Germing U, LeBeau MM, Porwit A, Baumann I et al. Myelodysplastic syndromes/neoplasms. In: Swerdlow SH et al. (eds). WHO Classification of Tumours and Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008, pp 88-93.
8. Arroyo JL, Fernandez ME, Hernandez JM, Orfao A, San Miguel JF, Del Canizo MC. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J 2004; 5: 227-233.
9. Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005; 19: 776-783.
10. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008; 112: 2681-2686.
11. Valent P, Orazi A, Busche G, Schmitt-Graff A, George TI, Sotlar K et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget 2010; 1: 483-496.
12. Stelzer GT, Shults KE, Loken MR. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann NY Acad Sci 1993; 677: 265-280.
13. Loken MR, van de Loosdrecht AA, Ogata K, Orfao A, Wells DA. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 2008; 32: 5-17.
14. Bjornsson S, Wahlstrom S, Norstrom E, Bernevi I, O'Neill U, Johansson E et al. Total nucleated cell differential for blood and bone marrow using a single tube in a five-color flow cytometer. Cytometry B Clin Cytom 2008; 74: 91-103.
15. Allan RW, Nsari-Lari MA, Jordan S. DRAQ5-based, no-lyse, no-wash bone marrow aspirate evaluation by flow cytometry. Am J Clin Pathol 2008; 129: 706-713.
16. Loken MR, Chu SC, Fritschle W, Kalnoski M, Wells DA. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom 2008; 76B: 27-36.
17. Brooimans RA, Kraan J, van Putten W, Cornelissen JJ, Lowenberg B, Gratama JW. Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1. Cytometry B Clin Cytom 2008; 76B: 18-26.
18. Knipp S, Strupp C, Gattermann N, Hildebrandt B, Schapira M, Giagounidis A et al. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res 2008; 32: 33-37.
19. Cesana C, Klersy C, Brando B, Nosari A, Scarpati B, Scampini L et al. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. Leuk Res 2008; 32: 1715-1723.
20. Alhan C, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Do peripheral blasts count in myelodysplastic syndromes? Leuk Res 2009; 33: 209-211.
21. Braulke F, Schanz J, Jung K, Shirneshan K, Schulte K, Schuetze C et al. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. Leuk Res 2010; 34: 1296-1301.
22. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-987.
23. Benesch M, Deeg HJ, Wells D, Loken M. Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. Hematology 2004; 9: 171-177.
24. Stachurski D, Smith BR, Pozdnyakova O, Andersen M, Xiao Z, Raza A et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008; 32: 215-224.
25. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores J et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008; 22: 1175-1183.
26. Wood BL. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med 2007; 27: 551-575, vii.
27. Font P, Subira D, Mtnez-Chamorro C, Castanon S, Arranz E, Ramiro S et al. Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. Leuk Res 2006; 30: 957-963.
28. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores-Montero J et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on A series of 56 patients. Cytometry B Clin Cytom 2010; 78: 154-168.
29. Monreal MB, Pardo ML, Pavlovsky MA, Fernandez I, Corrado CS, Giere I et al. Increased immature hematopoietic progenitor cells CD34 +CD38dim in myelodysplasia. Cytometry B Clin Cytom 2006; 70: 63-70.
30. Goardon N, Nikolousis E, Sternberg A, Chu WK, Craddock C, Richardson P et al. Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica 2009; 94: 1160-1163.
31. Westers TM, van der Velden VH, Alhan C, Bekkema R, Bijkerk A, Brooimans RA et al. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: Report from the Dutch Working Party on Flow Cytometry in MDS. Leuk Res 2012; 36: 422-430.
32. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43-70.
33. Ogata K, Della Porta MG, Malcovati L, Picone C, Yokose N, Matsuda A et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009; 94: 1066-1074.
34. Vikentiou M, Psarra K, Kapsimali V, Liapis K, Michael M, Tsionos K et al. Distinct neutrophil subpopulations phenotype by flow cytometry in myelodysplastic syndromes. Leuk Lymphoma 2009; 50: 401-409.
35. Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S et al. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 2005; 64: 9-17.
36. Lorand-Metze I, Ribeiro E, Lima CS, Batista LS, Metze K. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 2007; 31: 147-155.
37. Huizinga TW, van der Schoot CE, Jost C, Klaassen R, Kleijer M, von dem Borne AE et al. The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature 1988; 333: 667-669.
38. de Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AEG. Neutrophil Fc gamma RIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families. Blood 1995; 86: 2403-2413.
39. Moulding DA, Hart CA, Edwards SW. Regulation of neutrophil FcgammaRIIIb (CD16) surface expression following delayed apoptosis in response to GM-CSF and sodium butyrate. J Leukoc Biol 1999; 65: 875-882.
40. Wang L, Wells DA, Deeg HJ, Loken MR. Flow cytometric detection of nonneoplastic antigenic polymorphisms of donor origin after allogeneic marrow transplant: a report of two cases. Am J Clin Pathol 2004; 122: 135-140.
41. Elghetany MT, Davis BH. Impact of preanalytical variables on granulocytic surface antigen expression: a review. Cytometry B Clin Cytom 2005; 65: 1-5.
42. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002; 100: 3897-3902.
43. Nakao S, Sugimori C, Yamazaki H. Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure. Int J Hematol 2006; 84: 118-122.
44. Wang SA, Pozdnyakova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M et al. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica 2009; 94: 29-37.
45. Ando K, Tanaka Y, Hashimoto Y, Ohyashiki JH, Sugimori N, Nakao S et al. PNHphenotype cells in patients with idiopathic cytopenia of undetermined significance (ICUS) with megakaryocytic hypoplasia and thrombocytopenia. Br J Haematol 2010; 150: 705-707.
46. Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010; 78: 211-230.
47. Sconocchia G, Fujiwara H, Rezvani K, Keyvanfar K, El OF, Grube M et al. G-CSFmobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte. J Leukoc Biol 2004; 76: 1214-1219.
48. Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 2005; 124: 799-806.
49. Subira D, Font P, Villalon L, Serrano C, Askari E, Gongora E et al. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders? Transl Res 2008; 151: 240-245.
50. Lacronique-Gazaille C, Chaury MP, Le GA, Faucher JL, Bordessoule D, Feuillard J. A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica 2007; 92: 859-860.
51. Sternberg A, Killick S, Littlewood T, Hatton C, Peniket A, Seidl T et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005; 106: 2982-2991.
52. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006; 108: 1037-1044.
53. Maftoun-Banankhah S, Maleki A, Karandikar NJ, Arbini AA, Fuda FS, Wang HY et al. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes. Am J Clin Pathol 2008; 129: 300-308.
54. Ogata K. Diagnostic flow cytometry for low-grade myelodysplastic syndromes. Hematol Oncol 2008; 26: 193-198.
55. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood 1987; 69: 255-263.
56. Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 2006; 20: 549-555.
57. Maynadie M, Picard F, Husson B, Chatelain B, Cornet Y, Le RG et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002; 100: 2349-2356.
58. Pfeilstocker M, Karlic H, Nosslinger T, Sperr W, Stauder R, Krieger O et al. Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications. Leuk Lymphoma 2007; 48: 1900-1909.
59. Chu SC, Wang TF, Li CC, Kao RH, Li DK, Su YC et al. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leuk Res 2011; 35: 868-873.
60. Clark RE, Smith SA, Jacobs A. Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid. J Clin Pathol 1987; 40: 652-656.
61. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004; 57: 604-608.
62. Kussick SJ, Fromm JR, Rossini A, Li Y, Chang A, Norwood TH et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005; 124: 170-181.
63. Satoh C, Dan K, Yamashita T, Jo R, Tamura H, Ogata K. Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res 2008; 32: 699-707.
64. Truong F, Smith BR, Stachurski D, Cerny J, Medeiros LJ, Woda BA et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a nondiagnostic bone marrow: a prospective study. Leuk Res 2009; 33: 1039-1046.
65. Kern W, Haferlach C, Schnittger S, Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010; 116: 4549-4563.
66. Falco P, Levis A, Stacchini A, Ciriello MM, Geuna M, Notari P et al. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. Eur J Haematol 2011; 87: 409-418.